UBS Downgrades AppFolio to Neutral on Slower Unit Growth

Veeva Systems is drawing renewed attention after Eli Lilly committed to deploying its Vault CRM globally in August and Amgen followed in September, moving established customers onto the company's newer commercial platform. For the quarter ended July 31, Veeva reported revenue up 18% to $928 million, including 16% subscription growth, while GAAP operating income rose 40% to $275 million and adjusted diluted EPS climbed to $2.35 from $1.99. The company's updated full-year outlook calls for approximately $3.68 billion in revenue and adjusted diluted EPS of approximately $9.21. Veeva shares trade at roughly 29.7x forward earnings versus 15.5x for Salesforce, and the stock returned 61.1% between March 30 and October 5. Insider Monkey tracked 61 hedge funds holding Veeva in the second quarter, down from 62 in the first, with short interest at 3.35% of float.

BlackLine expanded its industry-specific financial operations modernization program, rolling out preconfigured transformation blueprints and templates for banking, insurance, energy, and life sciences, while also achieving PCI DSS compliance to strengthen security for high-volume payment card reconciliation in retail and financial services. The company said embedding industry expertise, AI-enabled workflows, and direct access to senior finance leaders into its platform is aimed at shortening deployment times and helping complex, highly regulated customers modernize core finance processes more quickly and with greater control. The product news comes alongside BlackLine's decision to expand its equity buyback authorization to US$600 million, a move that would deploy essentially all free cash flow into repurchases and could cushion per share metrics if revenue timing remains lumpy. BlackLine's narrative projects $1.0 billion in revenue and $168.4 million in earnings by 2029, requiring 11.9% yearly revenue growth and about a $133.6 million earnings increase from $34.8 million today, while some of the most optimistic analysts already assumed roughly US$1.0 billion in revenue and about US$216.6 million in earnings. The company's forecasts yield a $38.10 fair value, a 28% upside to its current price.

BlackLine has rolled out an expanded industry-focused modernization program featuring preconfigured transformation blueprints for finance teams. The initiative introduces new pre-built templates tailored for banking, insurance, energy, and life sciences customers. The company also recently attained PCI DSS compliance, targeting retailers and financial institutions that handle cardholder payment data. BlackLine runs cloud software that helps finance teams automate reconciliations, close processes, and other routine accounting work, and the push into sector-specific templates and security standards speaks directly to workflows in regulated areas such as banking, insurance, and energy-heavy industries.

BTIG analyst Nick Altmann said he is "incrementally excited" about ServiceTitan's artificial intelligence opportunity following the company's annual Pantheon event in Orlando, which drew more than 5,000 attendees. Altmann, who has a Buy rating and a $110 price target on ServiceTitan, said the main innovation highlights included a broader rollout of Max to the residential customer base along with a roofing and commercial pilot, Field AI and Demand AI packages, and Homh, a demand generation platform for agents and consumers. The company introduced a simplified pricing framework intended to create a clearer migration path into Max through Field AI at roughly a 40% discount versus Max and Demand AI at roughly a 20% discount. ServiceTitan also introduced the Atlas mobile app, launched Homh as a new consumer demand generation channel, and announced several partner ecosystem updates across booking, financial operations, supplier onboarding, and financing. Altmann said the key theme of the event was that ServiceTitan is well-positioned to capitalize on all five levels of AI adoption, with Max framed by management as the path toward a self-running, self-improving business model.

Veeva Systems reported that more than 175 emerging biotech companies now use its Veeva Basics platform for drug development. The company said its Data Quality System has processed and cleaned information for over 1 million subjects across more than 1,000 clinical studies. Management framed both updates as steps toward more automated clinical trial data handling for life sciences customers. Veeva Systems builds cloud software that helps drug makers manage clinical and commercial data, and the company said wider use of Veeva Basics and the Data Quality System gives it a deeper role in everyday workflows for emerging life sciences customers across multiple regions. The key data point to watch is how quickly Veeva discloses the next usage milestone for Veeva Basics customer counts or Data Quality System subject volumes.